MedTrace Logo

The Safety and Efficacy of Roflumilast Foam in HS

NCT07263230 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-02-11

No results posted yet for this study

Summary

This study investigates the efficacy of topical roflumilast foam in patients with HS.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

DRUG

Roflumilast 0.3% topical foam

Roflumilast foam, 0.3%, is a phosphodiesterase 4 inhibitor

Sponsors & Collaborators

Principal Investigators

  • Martina Porter, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2028-03-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07263230 on ClinicalTrials.gov